Haploidentical CD7 CAR T-cells induced remission in a patient with TP53 mutated relapsed and refractory early T-cell precursor lymphoblastic leukemia/lymphoma
Abstract Patients with relapsed/refractory early T-cell precursor lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) respond poorly to traditional therapy and have dismal prognosis. CD7 is a promising therapeutic targets for chimeric antigen receptor modified T cell therapy (CART) due to its widely expre...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Book |
| Published: |
BMC,
2022-02-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_f738c74456a74142bdfdba9feeb94ca5 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Hai-ping Dai |e author |
| 700 | 1 | 0 | |a Wei Cui |e author |
| 700 | 1 | 0 | |a Qing-ya Cui |e author |
| 700 | 1 | 0 | |a Wen-juan Zhu |e author |
| 700 | 1 | 0 | |a Hui-min Meng |e author |
| 700 | 1 | 0 | |a Min-qing Zhu |e author |
| 700 | 1 | 0 | |a Xia-ming Zhu |e author |
| 700 | 1 | 0 | |a Lin Yang |e author |
| 700 | 1 | 0 | |a De-pei Wu |e author |
| 700 | 1 | 0 | |a Xiao-wen Tang |e author |
| 245 | 0 | 0 | |a Haploidentical CD7 CAR T-cells induced remission in a patient with TP53 mutated relapsed and refractory early T-cell precursor lymphoblastic leukemia/lymphoma |
| 260 | |b BMC, |c 2022-02-01T00:00:00Z. | ||
| 500 | |a 10.1186/s40364-022-00352-w | ||
| 500 | |a 2050-7771 | ||
| 520 | |a Abstract Patients with relapsed/refractory early T-cell precursor lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) respond poorly to traditional therapy and have dismal prognosis. CD7 is a promising therapeutic targets for chimeric antigen receptor modified T cell therapy (CART) due to its widely expression in almost all T-cell malignancies. Here we present the anti-CD7 CART therapy in a 11-year-old male with TP53 mutated relapsed/refractory ETP-ALL/LBL. The patient suffered second relapse after haploidentical hematopoietic stem cell transplantation, showing resistance to 4 lines salvage therapies including venetoclax. Nanobody derived CD7-CART cells were manufactured by co-transducing CAR-T cells with a CD7 protein expression blocker. 70.5% of blasts (CD7 expression: 92.6%) and extensive extramedullary disease (mediastinal mass, enlarged lymph nodes and spleen) were observed prior to CD7-CART-cell therapy. A total of 5 × 106/kg donor-derived CD7-CART-cells were infused. Hematological and extramedullary remission were both achieved, with persistence of CD7-CART-cells be detected until the last followup at 96th days after the infusion. Reversible adverse effects including grade 3 cytokine release syndrome and macrophage activation syndrome were observed. This case demonstrated that CD7-CART was a potent and safe salvage therapy in relapsed/refractory ETP-ALL/LBL patient with high tumor burden. Trial registration: ClinicalTrials. gov, NCT04785833 , Registered on March 8, 2021, prospectively registered. | ||
| 546 | |a EN | ||
| 690 | |a Chimeric antigen receptor T-cells | ||
| 690 | |a CD7 | ||
| 690 | |a Early T-cell precursor lymphoblastic leukemia/lymphoma | ||
| 690 | |a Relapsed / refractory | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Biomarker Research, Vol 10, Iss 1, Pp 1-5 (2022) | |
| 787 | 0 | |n https://doi.org/10.1186/s40364-022-00352-w | |
| 787 | 0 | |n https://doaj.org/toc/2050-7771 | |
| 856 | 4 | 1 | |u https://doaj.org/article/f738c74456a74142bdfdba9feeb94ca5 |z Connect to this object online. |